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ABSTRACT 
Background 
The impact on children of patching versus atropine treatment for amblyopia was assessed 
XVLQJFKLOGUHQ¶VSHUVSHFWLYH+HDOWK5HODWHG4XDOLW\RI/LIe (HRQoL) scores in 5 to 7 year 
olds. 
Methods 
Forty-six children on the threshold of commencing either patching or atropine treatment for 
amblyopia were recruited. Treatment was prescribed for uniocular amblyopia of visual acuity 
(VA) 0.2 logMAR or worse. After four weeks of their chosen treatment, each child 
completed the Child Amblyopia Treatment Quality-of-Life Questionnaire (CAT-QoL). The 
Pediatric QuDOLW\RI/LIH,QYHQWRU\3HGV4/, Young Child (5-7) Self-Report version, was 
completed before and after four weeks of treatment. Quality of life scores were compared 
between the two treatment groups.  
Results 
Sixty-one percent (n=28) of participants were male and 56.5% (n=26) were white British. 
The CAT-QoL has a range of 0-16, with 16 being the worst quality of life. No significant 
difference was found between the patching group (n=30, mean age 69.7 months) and the 
atropine group (n=16, mean age 69.3 months) for CAT-QoL quality of life scores (Patch 
median = 6.3, Atropine median = 5.6, U = 199, p = .341, 95% CI of the median difference -
2.3 to 0.9). The Young Child (5-7) Self-5HSRUWYHUVLRQRIWKH3HGV4/KDV a µWRWDOVFRUH¶
range of 0-100, with 0 being the worst quality of life. There was also no significant difference 
LQ3HGV4/TXDOLW\RIOLIHtotal scores (Patch median = 80, Atropine median = 83.33, U 
=239.5, p = .991, 95% CI of the median difference -13.33 to 10) after four weeks of 
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treatment.  
Conclusion 
Amblyopic children reported that patching and atropine treatments did not have a significant 
impact on their quality of life. Patching and atropine should continue to be offered as first 
line treatments for amblyopia, as children appear to tolerate both well and do not favour one 
over the other.  
 
KEY WORDS; Amblyopia, Quality of Life, CAT-QoL 
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INTRODUCTION 
Amblyopia is the most common disorder to affect childhood vision, with prevalence 
estimated between 1% and 5.3%.1,2,3  By definition, amblyopia is a neurodevelopmental 
visual system condition caused by anomalous visual experience during the development of 
vision.4 It is characterised by diminished visual functions that usually, though not always, 
affect just one eye.5  Treatment for amblyopia is typically initiated before the end of the 
critical period of visual development; typically by the age of eight years, to gain the best 
chance of visual improvement; however treatment can improve visual acuity (VA) in the 
short term, in some patients up to age 17 years.6 The aim of amblyopia treatment is to achieve 
the best possible level of VA in the amblyopic eye by promoting its use. This is most 
commonly achieved either by wearing an occlusive eye patch (patching) over the non-
amblyopic eye for a number of hours per day,7,8,9,10 or by instilling the cycloplegic agent 
atropine sulphate 1% (atropine) into the non-amblyopic eye for a number of days per 
week.11,12,13,14 Both have been shown to be equally effective in the treatment of amblyopia 
and both are recommended as a first line treatment option.15,16 Despite this, the choice of first 
line amblyopia treatment is variable around the UK, with some areas offering patching as the 
first and then atropine as the second line treatment, whilst others offer parents and children 
the choice of treatment.17 
The treatment of amblyopia in childhood is justified by the reduced risk of incapacitating 
vision loss in later life.18,19 However, the treatment of amblyopia has the potential to affect a 
FKLOG¶VSV\FKRVRFLDOZHOO-being,20,21 and one study has shown that parents consider atropine 
KDVDOHVVHULPSDFWRQWKHFKLOG¶VTXDOLW\RIOLIHFRPSDUHGWRSDWFKLQJ22 The impact of 
amblyopLDWUHDWPHQWRQDFKLOG¶VTXDOLW\RIOLIHDVZHOODVWKHFRQGLWLRQLWVHOIDUH
increasingly recognised as important considerations. Quality of life assessments are widely 
available but amblyopia specific Health Related Quality of Life (HRQoL) instruments are 
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limited, especially those which capture the child¶s persepective.23 Many studies have used the 
Pediatric Quality of Life Inventory (PedsQL) to assess the impact of a variety of ocular 
conditions on general HRQoL.24,25,26 Each concluded that the PedsQL results should be 
interpreted with caution, as it may not be the most suitable or sensitive tool for assessing the 
impact of milder ocular conditions on HRQoL. A child version of the Amblyopia Treatment 
Index is available and has been used to evaluate the burden of amblyopia treatment from the 
SDUHQWDQGFKLOG¶VSHUVSHFWLYH27  The child version of the ATI is suitable for completion by 
children aged 7+ and therefore not the younger age groups that are more commonly treated 
for amblyopia.  The Child Amblyopia Treatment quality-of-life questionnaire (CAT-QoL) 
KDVEHHQGHYHORSHGWRDOORZWKH\RXQJHUFKLOG¶VDJHGWR\HDUVSHUVSHFWLYHRIDPEO\RSLD
treatment to be captured and considered.28,29,30 Therefore this study was designed to measure 
the impact of aPEO\RSLDWUHDWPHQWSDWFKLQJDQGDWURSLQHRQ+54R/IURPWKHFKLOG¶V
perspective using this newly developed, treatment specific CAT-QoL.  
MATERIALS AND METHODS  
Participants 
The study was conducted in the Orthoptic Department at Bradford Royal Infirmary, UK. 
Recruitment began in January and concluded in July. Children aged 5 to 7 years, on the 
threshold of commencing either patching or atropine treatment for amblyopia, were identified 
from their clinical notes on the day of their orthoptic appointment and invited to participate 
during their consultation. All children had previously had a normal fundus and media 
examination, refraction under cycloplegia and at least three months of refractive adaptation if 
glasses were required.5 Amblyopia treatment was offered when amblyopic eye VA was 0.2 
ORJ0$5RUZRUVH9$ZDVPHDVXUHGZLWKDFURZGHG9$WHVWDSSURSULDWHIRUHDFKFKLOG¶V
age and ability, either Keeler crowded LogMAR or LogMAR crowded Kay pictures. 
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Children with strabismic, anisometropic or strabismic and anisometropic (mixed) amblyopia 
were included. Previous treatment for amblyopia was not cause for exclusion from this study, 
providing no treatment had been done in the month prior to recruitment. Families were 
offered either patching or atropine and could FKRRVHWKHWKHUDS\WKH\SUHIHUUHGIRUWKHFKLOG¶V
DPEO\RSLDWUHDWPHQWµ3DWFKLQJ¶ZDVSUHVFULEHGEHWZHHQWRKRXUVSHUGD\DWWKHGLVFUHWLRQ
of the Orthoptist.8,9,31,32 µAtURSLQH¶ was 1% atropine drops prescribed for weekend instillation 
(i.e. instillation on Saturday and Sunday).11,12   
Excluded from the study were patients with ocular pathology causing reduced VA; children 
unable to complete the CAT-4R/RU3HGV4/TXHVWLRQQDLUHFKLOGUHQZKRKDGUHFHLYHG
amblyopia treatment during the previous month; and children who had not undertaken any 
treatment at the four-week follow-up visit. The study was given ethical and NHS approval 
and adhered to the tenets of the Declaration of Helsinki. Written informed consent from the 
parent or legal guardian and written assent from the child were obtained prior to enrolment in 
the study.  
Procedure 
Following the clinical decision to start amblyopia treatment, the parents and the child were 
offered the choice of patching or atropine. Participants were not allocated or randomised to a 
treatment group. 
Child pDUWLFLSDQWVFRPSOHWHGWKH3HGV4/ questionnaire (Young Child (5-7) Self-Report 
version) at clinic on the day that treatment was selected. A higher µWRWDOscore¶ (out of a 
maximum score of 100) indicates a better quality of life. At the four-week follow-up visit, 
adherence to the treatment prescribed was confirmed by asking the parents what regime had 
been done. For the patching group the amount of patching prescribed versus the actual 
amount of time worn was recorded.  
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The child then completed the CAT-4R/WUHDWPHQWVSHFLILFTXHVWLRQQDLUHDQGWKH3HGV4/
questionnaire (Young Child (5-7) Self-Report version) again.  
The CAT-QoL Questionnaire 
The CAT-QoL questionnaire is available in seven different versions; patch, drops, glasses, 
patch and drops, patch and glasses, glasses and drops, glasses, patch and drops. Each version 
is almost identical just with slightly different wording to make it applicable to the 
type/combination of amblyopia treatment. Relevant to this study werHWKHµSDWFK¶YHUVLRQDQG
WKHµGURSV¶YHUVLRQRQO\DVVXFKWKHFKLOGFRPSOHWHGZKLFKHYHU&$7-QoL version matched 
their treatment type.  The CAT-QoL has eight items (questions), which encompass physical, 
psychological and social aspects of daily life as follows; 
1. Sad 
2. Feeling of your patch/drops on your face 
3. Hurt 
4. Doing work at school 
5. How other children have treated you 
6. Doing things (like playing on the computer, colouring, playing games, watching TV) 
7. Worried 
8. Playing with my friends 
Each question has three response levels, scored either 0, 1 or 2, HJTXHVWLRQRQHµ6DG¶0\
Patch has not made me feel sad = 0, My patch has made me feel a bit sad = 1, My patch has 
made me feel very sad = 2). These raw scores are then totalled to give a score between 0-16. 
,QFRQWUDVWWRWKH3HGV4/DORZHUVFRUHLQGLFDWHVEHWWHUTXDOLW\RIOLIH7KH&$7-QoL 
comes with a Rasch scoring conversion chart (Table 1). The Rasch converted scores were 
used for this study (full details of the development and validation of the CAT-QoL and the 
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scoring system are available).33,34,35, 36  
All questionnaires were completed by the child, with their parent present, following the user 
LQVWUXFWLRQV/LFHQVHVIRUWKHXVHRIERWKWKH3HGV4/DQGWKH&$7-QoL were obtained for 
the purposes and duration of this study prior to commencement. 
The primary outcome measure was the CAT-QoL score after four weeks of treatment. The 
VHFRQGDU\RXWFRPHPHDVXUHZDVWKHFKDQJHLQ3HGV4/total score from pre-treatment to 
after 4 weeks of treatment. Following completion of the questionnaires after 4 weeks of 
treatment, the orthoptic examination took place. Clinical information was recorded including 
age, ethnicity, gender, glasses wearer, aetiology of amblyopia, VA, treatment group, and 
previous treatment. Data was statistically analysed using SPSS (IBM SPSS software package 
version 21).    
Statistics 
Non-parametric analyses were performed, as the results were skewed and did not follow a 
normal distribution. The Mann-Whitney U test was used to cRPSDUHWKH3HGV4/total 
scores of the patch and atropine group pre-treatment to ensure no differences existed prior to 
treatment commencement. It was also used to compare the CAT-QoL scores of the patch and 
DWURSLQHJURXSDIWHUZHHNVRIWUHDWPHQWDQGWKH3HGV4/total scores of the patch and 
atropine group after 4 weeks of treatment. Within each treatment group, the Wilcoxon Signed 
5DQNHGWHVWZDVXVHGWRFRPSDUH3HGV4/total scores pre-treatment to after 4 weeks of 
treatment. 
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RESULTS 
Forty-six participants were recruited to the study between January and July. The 
demographics of the patching and atropine groups are shown in Table 2. Thirty-three percent 
of the patching group and 56% of the atropine group had previously received treatment for 
amblyopia, although none had received any amblyopia treatment in the two months prior to 
enrolment in the study. The atropine group also included more children with poorer vision in 
their amblyopic eye (Table 2). 
Thirty (61%) opted for patching treatment and 16 (39%) opted for atropine eye drops. Sixty-
one percent (n=28) were male and 56.5% (n=26) were white British. Sixty-one percent of the 
males (n=17) and 72% of the females (n=13) chose patching. The average age of the 
participants was 69.7 months in the patching group (range 60-92 months) and 69.3 months in 
the atropine group (range 61-85 months). All but two of the participants wore glasses (n=44), 
of the two without glasses, one chose patching and the other chose atropine. The design of the 
study, which allowed patients and their parents to choose their treatment option, resulted in 
the patching group being almost double the atropine group in participant number.  
 
Reports of Problems with Treatment 
Four children in the patching group reported problems including not liking the stickiness on 
the face, being unable to see properly when the patch was on and the patch causing redness 
and soreness around the eye (one of these children requested to swap to atropine at the four 
week follow up visit). These 4 children managed to wear the patch less than half the 
prescribed number of hours. Five children reportedly wore their patch for 50-75% of the 
number of hours prescribed, 19 children reportedly wore their patch for the prescribed 
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number of hours and 2 children reportedly wore their patch for an hour more than that 
prescribed.  
Six children in the atropine group reported problems related to the anticipation and worry of 
having the drop instilled. Some parents reported having to physically restrain their child to 
instil atropine, causing distress and other parents reported instilling the atropine while the 
child was asleep. Two of these children requested to swap to patching at the four-week follow 
up visit. All children in the atropine group reportedly adhered to the weekend atropine 
instillation.  
3HGV4/6FRUHV 
7KH3HGV4/SUH-treatment total scores for both groups showed a negative skew towards 
better quality of life (Figure 1a). Importantly, using the Mann-Whitney U test, no significant 
difference in quality of life total scores between the two groups was evident prior to treatment 
(U= 232, p=.853, median for both patch and atropine groups = 80.0, 95% CI of the median 
difference = -10 ± 6.67) as shown in Table 3.  
 
The pre-WUHDWPHQW3HGV4/total scores were compared to the 3HGV4/total scores after 4 
weeks of treatment using the Wilcoxon signed-rank test. No significant difference between 
the total scores was found for the patching group (Z=-.817, p=.414, pre-treatment median = 
80.0, after 4 weeks of treatment median = 80.0), or for the atropine group (Z=-.439, p=.6603, 
pre-treatment median = 80, after 4 weeks of treatment median = 83.33). This indicates that 
four weeks of amblyopia treatment with patching or atropine did not significantly affect 
TXDOLW\RIOLIHDVPHDVXUHGE\WKH3HGV4/ 
 
The 3HGV4/total scores after 4 weeks of treatment showed a negative skew towards better 
quality of life in both groups (Figure 1b). Using the Mann-Whitney U test to compare the 
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3HGV4/results between the patching and atropine group after 4 weeks of treatment, no 
significant difference in total scores was found (U = 239.5, p = .991, patch median = 80.0, 
atropine median= 83.3, 95% CI of the median difference = -13.33 - 10) as shown in Table 3. 
 No difference was found in the scores from the different 3HGV4/<RXQJ&KLOG-7) Self-
Report version) domains (physical functioning (U = 236, p = .925), emotional functioning (U 
= 268.5, p = .485), social functioning (U = 248, p = .844) and school functioning (U = 247.5, 
p = .853)) between the patching and atropine groups.  
The 3HGV4/total scores after 4 weeks of treatment LQGLFDWHWKDWIURPWKHFKLOG¶V
perspective amblyopia treatment overall did not negatively affect their quality of life, with an 
overall median score for all participants (n=46) of 78.2 (SD 18.4) out of a possible 100.  
 
CAT-QoL Scores 
Following four weeks of amblyopia treatment the CAT-QoL questionnaire was completed by 
all 46 participants which showed an overall mean converted score of 5.6 (SD 2.9) out of a 
possible 16. Although the CAT-QoL atropine median (5.6) was lower (towards better QoL) 
than the patching median (6.3) (figure 2), the Mann-Whitney U test found no significant 
difference between atropine and patching after treatment (U = 199, p = .341, 95% CI of the 
median difference = -2.3 ± 0.9) as shown in Table 4. 
The response to each individual question of the CAT-QoL was compared between the patch 
and the atropine group using the independent samples Mann-Whitney U test (Table 5).  
 
 
Overall, the results from both WKH3HGV4/DQGWKH&$7-QoL found no significant negative 
impact of either treatment option on the child. The HRQoL scores as reported by the child 
(aged 5-7 years) show no statistically significant difference after receiving 4 weeks of 
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amblyopia treatment with either patching or atropine. The 95% confidence intervals for the 
PHGLDQ3HGV4/DQG&$7-QoL results, and the differences between the treatments, (shown 
in tables 3 and 4), demonstrate the similarity of the medians and lack of significant 
differences between treatments, however, the possibility of differences in a larger sample size 
cannot be ruled out.   
 
DISCUSSION 
This study aimed to measure, and compare, the impact of patching and atropine treatment, on 
the HRQoL of children with amblyopia, aged 5 to 7 years, using the CAT-QoL and the 
3HGV4/HRQoL questionnaires. Children reported no significant difference between 
patching and atropine within the first four weeks of treatment and both treatments had little 
negative impact on their HRQoL. To date there have been no other studies which have 
H[SORUHGDQGFRPSDUHGWKHHIIHFWRISDWFKLQJDQGDWURSLQHRQ+54R/IURPWKHFKLOG¶V
perspective in this age group. This may be because the availability of amblyopia specific 
HRQoL instruments for this age group is limited.23 One study has used a child version of the 
Amblyopia Treatment Index (ATI) to compare HRQoL scores in older children (aged 7 to 
<13 years) treated with atropine and those treated with patching.27 It was found that those 
treated with atropine had better overall QoL scores, and better scores on the subscales of 
compliance and social stigma. The adverse effects subscale was similar in both treatment 
groups. Interestingly, in contrast to this, our study showed a higher number of children in the 
atropine group reporting difficulties with carrying out the treatment and adverse effects. This 
could be due to the difference in age groups questioned. Our patching group may also have 
reported a lesser effect on QoL due to the relatively low number of hours per day that 
patching was prescribed in this study, giving the opportunity to carry out the treatment at 
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home away from peers. We also relied on the parents¶ reports of adherence to the treatment 
regime, whose accuracy may be questionable. These factors could have led to a reduced 
effect on reported quality of life in the patching group. 
Although an adult perspective may not truly represent the thoughts and feelings of the child, 
the view of the parent should not be disregarded, as their involvement in the treatment is 
paramount to success. Parents have reported that the use of a patch can cause problems with 
everyday life, schoolwork and can put a strain on the parent-child relationship.38 Parents find 
that implementing the treatment is not easy and is commonly associated with some level of 
distress.39 Parents have also identified significantly worse adverse effects to treatment, greater 
difficulty with treatment compliance and increased problems with social stigma when their 
child is patching compared to instilling atropine.40 Some atropine users have reported 
concerns about the appearance of the dilated pupil,41 but it is mostly patch users who feel that 
their treatment draws adverse attention to them with teasing and name calling frequently 
reported.20,21 One study reported that patch users had a significantly worse social acceptance 
score than atropine users.40 Our study found no statistically significant difference in the 
quality of life scores between the patching and atropine groups. In this study both patching 
and atropine were explained to the child and parent, which instigated a discussion about 
which treatment they would prefer to use. This gave the child the opportunity to voice any 
concerns about either treatment option prior to commencement. Some parents and children 
openly discussed the possibility of teasing if they were to choose the eye patch, and stated 
from the beginning that the patch could be worn only at home. This process of actively 
involving the child in their own treatment decisions has the potential to aid their 
understanding and tolerance of the treatment given, which may then have been reflected in 
the answers that they gave to the CAT-QoL at their four-week follow up visit. The lack of 
QHJDWLYHLPSDFWRQDFKLOG¶VVHOI-reported HRQoL during the first four weeks of amblyopia 
14 
 
treatment may have been positively influenced by involving children in the decision about 
their choice of treatment.  
We included children in the study who had previously undergone some amblyopia treatment, 
either patching or atropine. We acknowledge this may have influenced their responses to the 
quality of life questionnaires, positively or negatively.   
Despite children reporting amblyopia treatment causing little effect on their HRQoL, 
difficulties with adhering to the prescribed treatment were reported in both the patching and 
atropine group. Four children in the patching group reported problems including not liking 
the stickiness on the face, being unable to see properly when the patch was on and the patch 
causing redness and soreness around the eye. Six children in the atropine group reported 
problems related to the anticipation and worry of having the drop instilled, not to the after 
effects of the atropine (i.e. blurred VA or light sensitivity). Some parents reported having to 
physically restrain their child to instil atropine, causing distress and other parents reported 
instilling the atropine while the child was asleep. Difficulties with instilling weekend atropine 
may be worse than with daily atropine due to lack of routine,12,22 therefore a daily routine for 
the patch group versus a weekend only routine for the atropine group in this study could have 
influenced the results. One child in the patching group (3%) requested to swap to atropine 
and two children in the atropine group (12.5%) requested to swap to patching at the four-
week follow up visit. 
Study Limitations  
Nearly double the number of parents, after discussing treatment type with their child, chose 
patching over atropine. This is an interesting finding in itself in regard to treatment 
preference, but did result in unequal group sizes for our study. A future study comparing 
HRQoL measures in children who have had input into amblyopia treatment decisions to those 
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who have not is needed to understand how much this is a factor in their perceived HRQoL.    
It is also acknowledged that the CAT-QoL is a relatively new QoL instrument and therefore 
extensive validation results are not available. For this reason, the PedsQL was used as a 
secondary outcome measure, but it is recognised that this is not a disease/treatment specific 
HRQoL measure and its sensitivity when used in ocular conditions in younger age groups has 
been questioned.24,26 Future studies of larger, equally sized and matched groups of patients 
receiving amblyopia treatment for the first time and during the entire course of their 
amblyopia treatment would help address some of the limitations of this study. However, the 
findings of this study are encouraging in that during a four week course of amblyopia 
treatment there was no significant negative impact of either atropine or patching to perceived 
quality of life and no difference between the two interventions.  
 
Conclusions 
There was no difference in the HRQoL of children receiving patching treatment compared to 
those receiving atropine treatment. Four weeks of either patching or atropine treatment has 
minimal effect on the HRQoL of amblyopic children, aged 5 to 7 years. This is in contrast to 
previous studies that reported parents think atropine affects the HRQoL of their children less 
than patching. Our results suggest that offering a choice of patching or atropine as the first 
line treatment for amblyopia is appropriate, as children tolerate both equally well. 
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